[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@OzmosiHealth](/creator/twitter/OzmosiHealth)
"$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620686476021854) 2025-07-22 11:32:11 UTC 2633 followers, XXX engagements


"$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947643337483112663) 2025-07-22 13:02:11 UTC 2628 followers, XXX engagements


"$EVAX Evaxion to share two-year clinical efficacy results from phase X trial of AI-created personalized cancer vaccine EVX-01 at ESMO Congress 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738137603420212) 2025-07-25 13:32:32 UTC 2633 followers, XXX engagements


"$CRNX Crinetics will present new long-term data showing lasting control of oral PALSONIFY in Acromegaly at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944517755635630449) 2025-07-13 22:02:14 UTC 2633 followers, XXX engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $AGIO Agios will present Phase X Anemia Sickle Cell Data for Mitapivat (PKR Activator - Small Molecule) tomorrow 👀"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1932757800327000094) 2025-06-11 11:12:23 UTC 2633 followers, XXX engagements


"Sobi announces FDA approval of Doptelet for treating thrombocytopenia in children aged 1+ with persistent or chronic ITP. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948700335159345531) 2025-07-25 11:02:19 UTC 2633 followers, XXX engagements


"$WALD Waldencast buys Novaestiq Corp. and U.S. rights for Saypha injectable hyaluronic acid gel line under Obagi Medical brand. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947975586250662391) 2025-07-23 11:02:26 UTC 2633 followers, XXX engagements


"$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947250723793866964) 2025-07-21 11:02:05 UTC 2628 followers, XXX engagements


"$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-cel to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360684540219405) 2025-07-24 12:32:40 UTC 2633 followers, XXX engagements


"$HALO Halozyme reports argenx gains EU approval for VYVGART subcutaneous injection with ENHANZE to treat CIDP. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1936115212270325991) 2025-06-20 17:33:32 UTC 2633 followers, XXX engagements


"Pharma/Biotech Highlights: $MRNS: Marinus Pharma reports Q4 2023 earnings. $RYTM: Rhythm Pharma screens for obesity treatment. $NWPHF: Evenamide shows promise in treating TRS. $RARE: Ultragenyx's Evkeeza recommended in UK"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1743020790495289398) 2024-01-04 21:25:14 UTC 2627 followers, XXX engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943629425394045011) 2025-07-11 11:12:20 UTC 2633 followers, XXX engagements


"Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947484861507506475) 2025-07-22 02:32:28 UTC 2632 followers, XXX engagements


"$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945235025827651995) 2025-07-15 21:32:25 UTC 2630 followers, XXX engagements


"$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808936600514875) 2025-07-17 11:32:56 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947832210083746182) 2025-07-23 01:32:42 UTC 2630 followers, XXX engagements


"$BIVI BioVie showcased data at the 2nd World Conference on Aging highlighting potential age deceleration with Bezisterim treatment compared to placebo on XX different biological clocks. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360676050931980) 2025-07-24 12:32:38 UTC 2632 followers, XXX engagements


"$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942909752713134281) 2025-07-09 11:32:37 UTC 2633 followers, XXX engagements


"Aicuris completed enrollment for pivotal trial of Pritelivir for refractory herpes simplex in immunocompromised patients. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948308001208852954) 2025-07-24 09:03:19 UTC 2633 followers, XXX engagements


"CHMP recommends VORANIGO (vorasidenib) for Grade X IDH-mutant Diffuse Glioma in adults and adolescents. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948723006479761764) 2025-07-25 12:32:24 UTC 2633 followers, XXX engagements


"FDA fast tracks Addyi for postmenopausal women with low sexual desire enabling quicker access to treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360664092922144) 2025-07-24 12:32:35 UTC 2632 followers, XXX engagements


"$KRYS Jeune reports successful Phase X results for KB304 in treating moderate to severe dcollet wrinkles with noticeable aesthetic improvements. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360697089556878) 2025-07-24 12:32:43 UTC 2633 followers, XXX engagements


"$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939557671314817282) 2025-06-30 05:32:38 UTC 2633 followers, XXX engagements


"$PARIS:AB AB Science has been approved by multiple European countries to begin phase X study on masitinib for ALS. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948262436987187596) 2025-07-24 06:02:16 UTC 2633 followers, XXX engagements


"$AXDX Accelerate Diagnostics announces financial results for Q4 and full-year 2024. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1903266035685593583) 2025-03-22 02:02:38 UTC 2633 followers, XXX engagements


"Akeso starts Phase III trial of Ivonescimab for Pancreatic Cancer with first patient enrollment announced. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948194557948227758) 2025-07-24 01:32:32 UTC 2633 followers, XXX engagements


"$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945642697097908598) 2025-07-17 00:32:21 UTC 2633 followers, XXX engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Oncology Solid Tumor Unspecified Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940005523807772957) 2025-07-01 11:12:15 UTC 2633 followers, XXX engagements


"$AXSM Axsome Therapeutics resolves patent dispute over SUNOSI (solriamfetol) with Hetero Labs Ltd. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1927357641740751201) 2025-05-27 13:34:05 UTC 2633 followers, XXX engagements


"AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947681148131586117) 2025-07-22 15:32:26 UTC 2628 followers, XXX engagements


"$ATRA Pierre Fabre Pharmaceuticals Inc. reveals FDA acceptance and priority review of Biologics License Application for Tabelecleucel for EBV+ PTLD treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948368151680614402) 2025-07-24 13:02:20 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947839761181512142) 2025-07-23 02:02:42 UTC 2628 followers, XXX engagements


"Nxera Pharma to get $15M from Neurocrine Biosciences after dosing first patient in Phase X trial for NBI-1117568. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929682542350975244) 2025-06-02 23:32:24 UTC 2633 followers, XXX engagements


"$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744285708206082) 2025-07-14 13:02:23 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947764286136455425) 2025-07-22 21:02:48 UTC 2632 followers, 1498 engagements


"$ALPMY TYO:4503 VYLOY (zolbetuximab) approved by China's NMPA for first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1876064171642777971) 2025-01-06 00:32:08 UTC 2633 followers, XXX engagements


"Novo Nordisk's Alhemo (concizumab) may be approved to treat haemophilia A and B without inhibitors following positive opinion from European regulatory authority. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948700341593407540) 2025-07-25 11:02:21 UTC 2633 followers, XXX engagements


"Windward Bio begins global Phase X asthma trial for WIN378 an anti-TSLP monoclonal antibody with potential as long-acting and best-in-disease treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005787365986705) 2025-07-23 13:02:26 UTC 2633 followers, XXX engagements


"Inotrem introduces revolutionary precision medicine approach for Nangibotide trials in septic shock treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013356524445710) 2025-07-23 13:32:31 UTC 2633 followers, XXX engagements


"$IONS CHMP suggests approving TRYNGOLZA (olezarsen) in the EU for familial chylomicronemia syndrome (FCS). More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948707876895367500) 2025-07-25 11:32:17 UTC 2633 followers, XXX engagements


"The Phase II trial of KX-826 Tincture XXX% for male adult AGA in China met its primary endpoint. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948734629294604815) 2025-07-25 13:18:36 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947809437676408951) 2025-07-23 00:02:13 UTC 2629 followers, XXX engagements


"$VSTM Fast track designation granted to Verastem Oncology for VS-7375 in treating KRAS G12D-mutated Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345506125750460) 2025-07-24 11:32:21 UTC 2632 followers, XXX engagements


"$PARIS:AB AB Science has received approval from several European countries to begin the confirmatory phase X study with masitinib in ALS. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948285139425054772) 2025-07-24 07:32:29 UTC 2633 followers, XXX engagements


"$VIR First patient dosed in Phase X trial of EGFR-targeting VIR-5525 for solid tumors by Vir Biotechnology. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360703917875604) 2025-07-24 12:32:45 UTC 2633 followers, XXX engagements


"$IDYA IDEAYA Biosciences to present Phase X Clinical Trial of Neoadjuvant Darovasertib at ESMO 2025 for Primary Uveal Melanoma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375737167409474) 2025-07-24 13:32:29 UTC 2633 followers, XXX engagements


"First patient dosed in Phase 1b/2a trial of Procizumab a monoclonal antibody targeting shock's biological driver. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947960470293684531) 2025-07-23 10:02:22 UTC 2626 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947794374701793596) 2025-07-22 23:02:21 UTC 2633 followers, XXX engagements


"$ARVN Arvinas reveals preclinical data for ARV-393 a PROTAC BCL6 Degrader at the 2025 EHA Congress. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1933487579435053441) 2025-06-13 11:32:16 UTC 2633 followers, XXX engagements


"$HALO DARZALEX Faspro approved by EU Commission for adult patients with Smouldering Multiple Myeloma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948051067931177115) 2025-07-23 16:02:22 UTC 2632 followers, XXX engagements


"$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635807444959541) 2025-07-22 12:32:16 UTC 2629 followers, XXX engagements


"$ONCY TSX:ONC Key Opinion Leader Event sheds light on Pelareorep's promising data in pancreatic and gastrointestinal fields highlighting its future potential. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020937611464916) 2025-07-23 14:02:38 UTC 2633 followers, XXX engagements


"$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273427477549322) 2025-07-21 12:32:18 UTC 2632 followers, XXX engagements


"$CADL Candel Therapeutics obtains EMA Orphan Designation for CAN-2409 for Pancreatic Cancer treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360670141141441) 2025-07-24 12:32:37 UTC 2632 followers, XXX engagements


"$BCDA BioCardia wants to meet with Japan PMDA to talk about getting approval for CardiAMP Cell Therapy in Ischemic Heart Failure. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375730641043774) 2025-07-24 13:32:27 UTC 2633 followers, XXX engagements


"$ALPMY TYO:4503 FDA expands label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1889827478719656033) 2025-02-13 00:02:36 UTC 2633 followers, XXX engagements


"$RVMD Revolution Medicines announces publication in Science on Zoldonrasib a selective inhibitor for RAS(ON) G12D. Discovery and development detailed in peer-reviewed paper. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948473855816659447) 2025-07-24 20:02:22 UTC 2633 followers, XXX engagements


"$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940456256696996052) 2025-07-02 17:03:18 UTC 2627 followers, XXX engagements


"$PHGE BiomX starts Phase 2b trial for BX004 in Cystic Fibrosis patients first patient dosed successfully. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744294470078780) 2025-07-14 13:02:26 UTC 2633 followers, XXX engagements


"$GILD European Medicines Agency grants Gilead positive CHMP opinions for twice-yearly Lenacapavir for HIV prevention under accelerated review. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948647479479845145) 2025-07-25 07:32:17 UTC 2633 followers, XXX engagements


"$RVMD FDA grants Breakthrough Therapy Designation to Revolution Medicines' Elironrasib. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998237060964513) 2025-07-23 12:32:26 UTC 2633 followers, XXX engagements


"Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635820032032822) 2025-07-22 12:32:19 UTC 2627 followers, XXX engagements


"ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635814181310641) 2025-07-22 12:32:18 UTC 2626 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947786816930910555) 2025-07-22 22:32:19 UTC 2630 followers, XXX engagements


"Canada approves Blenrep combos for relapsed/refractory multiple myeloma treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947983118478278810) 2025-07-23 11:32:21 UTC 2632 followers, XXX engagements


"Bayer shares regulatory update on Elinzanetant for treating moderate to severe menopause-induced hot flashes. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948790970214219824) 2025-07-25 17:02:28 UTC 2633 followers, XXX engagements


"$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736748279627979) 2025-07-14 12:32:26 UTC 2633 followers, XXX engagements


"Apnimed announces positive results from Phase X trial of AD109 showing potential as first oral pill for obstructive sleep apnea. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947968042648154326) 2025-07-23 10:32:27 UTC 2632 followers, XXX engagements


"$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946178701269611001) 2025-07-18 12:02:15 UTC 2626 followers, XXX engagements


"Ammonium Chloride Market projected to reach $XXXX billion by 2034. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948043747507544398) 2025-07-23 15:33:16 UTC 2632 followers, XXX engagements


"$BMRN BioMarin shares five-year Phase X data confirming effectiveness and safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1937504076075532326) 2025-06-24 13:32:23 UTC 2633 followers, XXX engagements


"$SLDB FDA grants Fast Track Designation to Solid Biosciences for SGT-501 a first-of-its-kind gene therapy for CPVT. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998243591500270) 2025-07-23 12:32:27 UTC 2632 followers, XXX engagements


"$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947711300655845785) 2025-07-22 17:32:15 UTC 2630 followers, XXX engagements


"$IMAB I-Mab acquires Bridge Health to enhance Givastomig IP portfolio. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808968561160397) 2025-07-17 11:33:04 UTC 2633 followers, XXX engagements


"$CELC First patient in Phase X VIKTORIA-2 trial of Gedatolisib for HR+/HER2Advanced Breast Cancer dosed by Celcuity as first-line treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948481423783936447) 2025-07-24 20:32:27 UTC 2633 followers, XXX engagements


"$KALV KalVista Pharmaceuticals gets favorable CHMP view for Sebetralstat for the management of Hereditary Angioedema Attacks. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948723012272095368) 2025-07-25 12:32:26 UTC 2633 followers, XXX engagements


"Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947650899213750497) 2025-07-22 13:32:14 UTC 2627 followers, XXX engagements


"$ACET Adicet Bio dosed the first Systemic Sclerosis patient in Phase X trial of ADI-001 for Autoimmune Diseases. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338030974226558) 2025-07-24 11:02:39 UTC 2633 followers, XXX engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Gastrointestinal Cancer Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940005524449419621) 2025-07-01 11:12:15 UTC 2633 followers, XXX engagements


"ANZUPGO Cream is the first FDA-approved treatment for moderate-to-severe Chronic Hand Eczema in adults. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948126569308000548) 2025-07-23 21:02:23 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947816984931868798) 2025-07-23 00:32:12 UTC 2629 followers, XXX engagements


"$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620700803792908) 2025-07-22 11:32:14 UTC 2626 followers, 1181 engagements


"$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338024838013218) 2025-07-24 11:02:38 UTC 2633 followers, XXX engagements


"$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258350670127142) 2025-07-21 11:32:23 UTC 2633 followers, XXX engagements


"$TNXP Tonix Pharmaceuticals will present new data on Mpox and smallpox vaccine TNX-801 at Vaccine Congress 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272668029219032) 2025-07-10 11:34:42 UTC 2633 followers, 3297 engagements


"$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823930666934771) 2025-07-17 12:32:31 UTC 2632 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947771757282398451) 2025-07-22 21:32:29 UTC 2629 followers, XXX engagements


"$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947265857270534315) 2025-07-21 12:02:13 UTC 2630 followers, XXX engagements


"$IMAB I-Mab shows promising data on Givastomig in combo with immunotherapy in 1L gastric cancer patients at ESMO GI 2025. Phase 1b results are positive. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940433407454109867) 2025-07-02 15:32:30 UTC 2633 followers, XXX engagements


"$BIIB SAGE CHMP gives positive opinion for ZURZUVAE in treating postpartum depression in women. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948707870725603800) 2025-07-25 11:32:16 UTC 2633 followers, XXX engagements


"$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273409840488919) 2025-07-21 12:32:14 UTC 2633 followers, XXX engagements


"$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939784175571345836) 2025-06-30 20:32:41 UTC 2633 followers, XXX engagements


"$PARIS:SAN Sanofi's Sarclisa granted EU approval for treating eligible newly diagnosed multiple myeloma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948610358434025668) 2025-07-25 05:04:47 UTC 2633 followers, XXX engagements


"$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947628237364072806) 2025-07-22 12:02:11 UTC 2633 followers, XXX engagements


"Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947447166949331097) 2025-07-22 00:02:41 UTC 2632 followers, XXX engagements


"Prilenia and Ferrer give news on European process for Pridopidine in Huntington's Disease regulatory approval. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738125125353707) 2025-07-25 13:32:29 UTC 2633 followers, XXX engagements


"$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946163606707667256) 2025-07-18 11:02:16 UTC 2633 followers, XXX engagements


"$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944759376243544306) 2025-07-14 14:02:21 UTC 2631 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947779263241101458) 2025-07-22 22:02:19 UTC 2629 followers, XXX engagements


"Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947567825000009931) 2025-07-22 08:02:08 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947847592425230474) 2025-07-23 02:33:49 UTC 2633 followers, XXX engagements


"Long-acting fully human anti-TSLP antibody HBM9378/WIN378 enters global Phase X POLARIS trial for asthma treatment. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020944741818570) 2025-07-23 14:02:40 UTC 2633 followers, XXX engagements


"$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076458277495035) 2025-07-15 11:02:20 UTC 2633 followers, XXX engagements


"$UNCY Unicycive Therapeutics releases Oxylanthanum Carbonate trial results in Clinical Journal of the American Society of Nephrology. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360691016241171) 2025-07-24 12:32:42 UTC 2633 followers, XXX engagements


"$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001 an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345499792322822) 2025-07-24 11:32:20 UTC 2633 followers, XXX engagements


"$LTRN Lantern Pharma announces full response in highly treated lymphoma patient with LP-284 in Phase X trial. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947990646461231375) 2025-07-23 12:02:16 UTC 2633 followers, XXX engagements


"$LLY CHMP has given a positive opinion on Donanemab for use in early symptomatic Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948692964756303932) 2025-07-25 10:33:02 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports promising Phase X findings on ABTECT 8-Week Induction Trials for Obefazimod an oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947757076627001502) 2025-07-22 20:34:09 UTC 2633 followers, 1011 engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947801890529677601) 2025-07-22 23:32:13 UTC 2630 followers, XXX engagements


"$KRYS Japan's Ministry of Health Labour and Welfare approves Krystal Biotech's VYJUVEK for treating Dystrophic Epidermolysis Bullosa. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738131379060971) 2025-07-25 13:32:30 UTC 2633 followers, XXX engagements


"$ENVB Enveric Biosciences gets second U.S. patent allowance for non-hallucinogenic mescaline derivatives in EVM401 Series. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998249929072722) 2025-07-23 12:32:29 UTC 2633 followers, XXX engagements


"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947824536189342085) 2025-07-23 01:02:12 UTC 2630 followers, XXX engagements


"Pharma/Biotech Highlights: $CBIO: FDA accepts Catalyst Pharma's S-NDA advancing FIRDAPSE. $ARDX: Ardelyx presents XPHOZAH data at Kidney Week. $THTX: Study reports findings on Trogarzo administration. $LBTSF: Almirall's Lebrikizumab aids dermatitis patients"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1712930096711979428) 2023-10-13 20:35:34 UTC 2633 followers, 1272 engagements


"$CYTK Cytokinetics reveals five presentations on Aficamten at ESC Congress 2025. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272645786767545) 2025-07-10 11:34:37 UTC 2633 followers, XXX engagements


"$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945114198767514092) 2025-07-15 13:32:18 UTC 2633 followers, 2776 engagements


"Kelun-Biotech's partner Windward Bio starts global Phase X trial for SKB378/WIN378 in asthma. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013362295763063) 2025-07-23 13:32:32 UTC 2634 followers, XXX engagements


"$RCKT FDA Clinical Hold on RP-A501 Trial causes Rocket Pharmaceuticals (RCKT) stock to plummet and leads to Class Action lawsuit by Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948149744532144136) 2025-07-23 22:34:28 UTC 2633 followers, XXX engagements


"$DYN Dyne Therapeutics receives FDA Breakthrough Therapy Designation for DYNE-101 in DM1 plans for accelerated approval discussed in Type C Meeting. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1934929648636580017) 2025-06-17 11:02:32 UTC 2632 followers, XXX engagements


"$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258375143817664) 2025-07-21 11:32:29 UTC 2632 followers, XXX engagements


"Alkeus Pharmaceuticals to present Gildeuretinol data at ASRS 43rd Annual Meeting on July 29-August X. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998230656303521) 2025-07-23 12:32:24 UTC 2633 followers, XXX engagements


"$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947280960367804609) 2025-07-21 13:02:14 UTC 2632 followers, XXX engagements


"Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002 a new treatment for Sickle Cell Disease. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948111515078504861) 2025-07-23 20:02:34 UTC 2633 followers, XXX engagements


"$CMND CSE:CMND Clearmind Medicine finishes starting trial at top Israeli site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. More Info: $XBI $IBB $XPH $PPH"  
![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1055982930.png) [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005780361495026) 2025-07-23 13:02:24 UTC 2633 followers, XXX engagements